Patents by Inventor Thomas Lundback

Thomas Lundback has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11471446
    Abstract: The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterized by reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic disorders.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: October 18, 2022
    Assignee: LU LICENSE AB
    Inventors: Johan Flygare, Lars Johansson, Thomas Lundbäck
  • Publication number: 20190111034
    Abstract: The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterized by reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic disorders.
    Type: Application
    Filed: November 3, 2016
    Publication date: April 18, 2019
    Inventors: Johan FLYGARE, Lars JOHANSSON, Thomas LUNDBÄCK
  • Patent number: 9523693
    Abstract: The present invention concerns a method of determining whether a non-purified sample contains a target protein bound to a ligand of interest comprising the steps of a) exposing the non-purified sample to a temperature which is capable of causing or enhancing precipitation of the unbound target protein to a greater extent than it is capable of causing or enhancing precipitation of the target protein bound to the ligand; and b) analyzing said sample for the presence of soluble or native target protein using two or more affinity reagents capable of binding to said soluble or native target protein with a higher affinity than to an unfolded and/or insoluble form of said target protein. The invention particularly concerns the use of two affinity reagents (e.g. antibodies) which are capable of distinguishing between soluble or native, and unfolded and/or insoluble forms of a target protein and whose detection e.g. by FRET based technology, allows the performance of the method without a separation step.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: December 20, 2016
    Assignee: Biotarget Engagement Interest Group AB
    Inventors: Pär Nordlund, Daniel Martinez Molina, Thomas Lundbäck
  • Patent number: 9233946
    Abstract: A compound of formula (I), wherein A is S, O or a double bond, and L is a substituted thiazolyl, phenyl or pyridyl. The compound is useful for the treatment of inflammation and cancer.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: January 12, 2016
    Assignee: KANCERA AB
    Inventors: Styrbjorn Bystrom, Charles Hedgecock, Evert Homan, Thomas Lundback, Jessica Martinsson, Meral Sari, Katarina Farnegardh, Mattias Jonsson
  • Publication number: 20150133336
    Abstract: The present invention concerns a method of determining whether a non-purified sample contains a target protein bound to a ligand of interest comprising the steps of a) exposing the non-purified sample to a temperature which is capable of causing or enhancing precipitation of the unbound target protein to a greater extent than it is capable of causing or enhancing precipitation of the target protein bound to the ligand; and b) analysing said sample for the presence of soluble or native target protein using two or more affinity reagents capable of binding to said soluble or native target protein with a higher affinity than to an unfolded and/or insoluble form of said target protein. The invention particularly concerns the use of two affinity reagents (e.g. antibodies) which are capable of distinguishing between soluble or native, and unfolded and/or insoluble forms of a target protein and whose detection e.g. by FRET based technology, allows the performance of the method without a separation step.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventors: Pär NORDLUND, Daniel Martinez MOLINA, Thomas LUNDBÄCK
  • Publication number: 20130172339
    Abstract: A compound of formula (I), wherein A is S, O or a double bond, and L is a substituted thiazolyl, phenyl or pyridyl. The compound is useful for the treatment of inflammation and cancer.
    Type: Application
    Filed: September 19, 2011
    Publication date: July 4, 2013
    Applicant: KANCERA AB
    Inventors: Styrbjorn Bystrom, Charles Hedgecock, Evert Homan, Thomas Lundback, Jessica Martinsson, Meral Sari, Katarina Farnegardh, Mattias Jonsson
  • Publication number: 20080255153
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, which are useful as inhibitors of human stearoyl-CoA desaturase (SCD). The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, metabolic syndrome, neurological diseases, immune disorders, cancer and various skin diseases.
    Type: Application
    Filed: March 27, 2008
    Publication date: October 16, 2008
    Applicant: BIOVITRUM AB (publ)
    Inventors: Ulf Bremberg, Auri Linden, Thomas Lundback, Jonas Nilsson, Marie Wiik, Magnus Bergner, Peter Brandt, Kristin Hammer, Rune Ringom
  • Publication number: 20080221129
    Abstract: The present invention relates to compounds of the formula (I): including pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, and N-oxides thereof, said compounds being useful as inhibitors of stearoyl-CoA desaturase (SCD). The invention further relates to the use of compounds of the formula (I) for treatment of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, neurological diseases, immune disorders, cancer, essential fatty acid deficiency, acne, psoriasis, rosacea or other skin conditions.
    Type: Application
    Filed: July 6, 2007
    Publication date: September 11, 2008
    Inventors: Thomas Lundback, Isabel Climent-Johansson, Jan Vagberg, Auri Linden, Jonas Nilsson, Marie Wiik, Ulf Bremberg
  • Patent number: 6586188
    Abstract: According to the invention &bgr;-tubulin, as well as a 65 kDa polypeptide present in pancreatic &bgr;-cells, have been identified as molecular targets for sulfonylurea compounds. These findings enable for the identification of new insulin secretagogues. The invention thus relates to the use of sulfonylurea compounds, such as e.g. glibenclamide, in methods for identification of compounds binding the 65 kDa polypeptide or tubulin, or stimulating tubulin polymerization and/or turnover, thereby stimulating insulin secretion.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: July 1, 2003
    Assignee: Biovitrum AB
    Inventors: Per-Olof Berggren, Thomas Lundbäck, Alejandro Bertorello